- Home
- UBFO vs ACIU Comparison
UBFO vs ACIU Comparison
Compare UBFO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- ACIU
- Stock Information
- Founded
- UBFO 1987
- ACIU 2003
- Country
- UBFO United States
- ACIU Switzerland
- Employees
- UBFO N/A
- ACIU N/A
- Industry
- UBFO Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- UBFO Finance
- ACIU Health Care
- Exchange
- UBFO Nasdaq
- ACIU Nasdaq
- Market Cap
- UBFO 162.0M
- ACIU 189.1M
- IPO Year
- UBFO N/A
- ACIU 2016
- Fundamental
- Price
- UBFO $8.64
- ACIU $2.07
- Analyst Decision
- UBFO
- ACIU Strong Buy
- Analyst Count
- UBFO 0
- ACIU 1
- Target Price
- UBFO N/A
- ACIU $12.00
- AVG Volume (30 Days)
- UBFO 115.6K
- ACIU 125.1K
- Earning Date
- UBFO 07-29-2025
- ACIU 08-05-2025
- Dividend Yield
- UBFO 5.50%
- ACIU N/A
- EPS Growth
- UBFO N/A
- ACIU N/A
- EPS
- UBFO 0.65
- ACIU N/A
- Revenue
- UBFO $45,108,000.00
- ACIU $32,014,254.00
- Revenue This Year
- UBFO N/A
- ACIU N/A
- Revenue Next Year
- UBFO N/A
- ACIU $533.21
- P/E Ratio
- UBFO $13.43
- ACIU N/A
- Revenue Growth
- UBFO N/A
- ACIU 91.20
- 52 Week Low
- UBFO $7.30
- ACIU $1.43
- 52 Week High
- UBFO $10.49
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- UBFO 52.50
- ACIU 55.57
- Support Level
- UBFO $8.46
- ACIU $2.00
- Resistance Level
- UBFO $8.96
- ACIU $2.15
- Average True Range (ATR)
- UBFO 0.23
- ACIU 0.13
- MACD
- UBFO -0.01
- ACIU -0.01
- Stochastic Oscillator
- UBFO 41.46
- ACIU 80.92
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.